Cyteir Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing the oncology medicines that inhibit deoxyribonucleic acid damage repair and cause cancer cell death in specific subsets of cancer patients through a therapeutic strategy known as synthetic lethality. Co.'s primary program, CYT-0851, was identified through a phenotypic screening strategy that exploited a synthetic lethality between cytidine deaminases (CD) overexpression and homologous recombination inhibition. The screen was designed to select for compounds that induced synthetic lethality in CD-overexpressing cancer cells while sparing normal cells.

CYT — News

CYT — Price Chart